A Phase 3 interventional study of Inrathecal Morphine and Intravenous Methadone in Testicular Cancer, sponsored by Indiana University. Recruiting at 2 sites in United States. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Indiana University · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.
Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2024, is one of 16 in phase 3, reaches primary completion later than 4 of the 25 other live ones, and was the 153rd registered.
295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.
Browse Testicular Neoplasms studies →21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
University of Arizona · Sites in United States
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
City of Hope Medical Center · Sites in United States
Ages 18+ · Men only
AstraZeneca · Sites in United States
Ages 18–130
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 52 · Phase 3 16
First in 1990; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 50 across 190 interventional studies indexed under Testicular Neoplasms.
Median enrollment 36 across the 111 interventional studies, 167 across the 35 observational. Of the 135 that completed or were terminated, 33 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 167 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 3 studies filed under Testicular Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Testicular Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06593665Phase 3Indiana UniversityIntrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. | 2026-12-31 |
| NCT07259304University of Southern CaliforniaSocial Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | 2026-12-31 |
| NCT04435756SWOG Cancer Research NetworkA Study of miRNA 371 in Patients With Germ Cell Tumors | 2027-01-01 |
| NCT06673329Brian Henick, MDBrodalumab in the Treatment of Immune-Related Adverse Events | 2027-05 |
| NCT07406087Kaiser PermanenteNavigation Intervention for Adolescent and Young Adult Cancer Survivors | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 167 studies in Testicular Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.
In this study, investigators aim to compare intravenous methadone combined with standard multimodal analgesia and surgical infiltration of local anesthesia to intrathecal duramorph with standard multimodal analgesia and surgical infiltration of local anesthesia. In this single blinded prospective randomized control trial, investigators hypothesize that intravenous methadone will provide a significant reduction in patient opioid consumption when compared to intrathecal opioid analgesia in the first 24 hours in patients who undergo PC/RPLND.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
Drug: Inrathecal Morphine
Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
Drug: Intravenous Methadone
Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
IV morphine equivalent (MME)
Cumulative Milligrams of morphine equivalent (MME) consumption
Time frame: First 24 hours postoperative
Opioid consumption
Opioid consumption in morphine equivalent (MME)
Time frame: 1 hour after arrival time to post anesthesia care unit
Opioid consumption
Opioid consumption in morphine equivalent (MME)
Time frame: 12 hours after arrival time to post anesthesia care unit
Opioid consumption
Opioid consumption in morphine equivalent (MME)
Time frame: 24 hours after arrival time to post anesthesia care unit
Opioid side effect-Nausea
Incidence of opioid side effects-nausea
Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study
Opioid side effects-Vomiting
Incidence of opioid side effects-vomiting
Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study
Opioid side effects-Pruritis
Incidence of opioid side effects-pruritis
Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study
Adverse Events
Incidence of adverse events
Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study
Opioid side effects-Respiratory Depression
Incidence of opioid side effects-respiratory depression
Time frame: after arrival time to post anesthesia care unit until 24 hours/completion of study
Pain Scores
Visual Analog Scale (VAS) pain score On a scale of 1 to 10 (increments of 1 unit), 1 being no pain at all, 10 being the most pain the patient has ever experienced
Time frame: 24 hours after arrival time to post anesthesia care unit
Pain Scores
Visual Analog Scale (VAS) pain score On a scale of 1 to 10 (increments of 1 unit), 1 being no pain at all, 10 being the most pain the patient has ever experienced
Time frame: 12 hours after arrival time to post anesthesia care unit
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone